由国际骨髓瘤学会(IMS)主办的第19届国际骨髓瘤学会年会将于2022年8月25日~27日在在美国洛杉矶举行,旨在汇集全球多发性骨髓瘤领域和相关浆细胞疾病的研究热点和最新进展,推动临床和实验室转化研究发展,促进国际专家学者深度交流。
近年来,中国在多发性骨髓瘤的诊治水平上越来越接近国际水准,此次2022第19届IMS上更是有多个来自中国的研究成果亮相,再次向全球展示了我们中国的科研与临床水平!我们先看看本次大会上入选的中国研究都有哪些?
33篇中国研究入选Poster专场
天津医科大学总医院
1.摘要号:P-014
标题:High function, but low level stem cell memory T cells in multiple myeloma: a potential tumor targeted and long lived cell therapy population.
通讯作者:付蓉
单位:天津医科大学总医院
2.摘要号:P-049
标题:Detection of multiple myeloma cell load by multiple-color flow cytometry as a useful approach for analyzing immune cell subsets in patients.
通讯作者:付蓉
单位:天津医科大学总医院
3.摘要号:P-050
标题:Detecting of myeloma cell-derived MPs by flow cytometry as a potential strategy to reflect minimal residual disease in MM patients.
通讯作者:付蓉
单位:天津医科大学总医院
4.摘要号:P-088
标题:Bone marrow mesenchymal stem cells regulate the function of NK cells via TIM-3/Gal-9 in multiple myeloma.
通讯作者:付蓉
单位:天津医科大学总医院
5.摘要号:P-139
标题:Pim-2 kinase regulate the expression of TIGIT and function of NK cells from multiple myeloma patients.
通讯作者:付蓉
单位:天津医科大学总医院
复旦大学附属中山医院
1.摘要号:P-027
标题:Lenalidomide does not affect platelet function in vitro.
通讯作者:刘澎
单位:复旦大学附属中山医院
2.摘要号:P-118
标题:Three distinct destines of malignant plasma cells based on single-cell transcriptomes and evolutionary trajectories.
通讯作者:刘澎
单位:复旦大学附属中山医院
3.摘要号:P-227
标题:The prognostic role of 1q21 gain/amp in newly diagnosed multiple myeloma: the faster, the worse.
通讯作者:刘澎
单位:复旦大学附属中山医院
北京协和医院
1.摘要号:P-029
标题:The association of microbiota composition and proteasome inhibitor-related gastrointestinal adverse effects.
通讯作者:庄俊玲
单位:北京协和医院
2.摘要号:P-035
标题:Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China.
通讯作者:庄俊玲
单位:北京协和医院
3.摘要号:P-037
标题:Chinese herbal medicine ‘Diwu’ suppresses myeloma bone disease via ERK/MAPK signaling pathway by targeting CCL3.
通讯作者:庄俊玲
单位:北京协和医院
4.摘要号:P-045
标题:Minimal residual disease detected by a novel isotope labeled PET/CT combined with next-generation flowcytometry in newly diagnosed multiple myeloma.
通讯作者:庄俊玲
单位:北京协和医院
中国医学科学院血液病医院
1.摘要号:P-044
标题:Genetically undetectable and negative minimal residual disease after induction therapy are equally important for survival in multiple myeloma.
通讯作者:安刚
单位:中国医学科学院血液病医院
2.摘要号:P-048
标题:The value of autologous hematopoietic stem cell transplantation in multiple myeloma patients with MRD negative after early induction therapy.
通讯作者:安刚
单位:中国医学科学院血液病医院
3.摘要号:P-054
标题:Neoplastic plasma cells in stem cell collection have no effect on the survival of multiple myeloma patients receiving autologous stem cell transplantation.
通讯作者:安刚
单位:中国医学科学院血液病医院
4.摘要号:P-061
标题:Differential expression profile and bioinformatic analysis of serum exosomal miRNA in multiple myeloma patients.
通讯作者:邱录贵
单位:中国医学科学院血液病医院
5.摘要号:P-089
标题:Disordered metabolism mediates the immunosuppressive microenvironment in multiple myeloma.
通讯作者:郝牧
单位:中国医学科学院血液病医院
6.摘要号:P-095
标题:Exosomal miR-27b-3p suppresses CD28 expression in T cells and facilitates immune escape of multiple myeloma.
通讯作者:郝牧
单位:中国医学科学院血液病医院
7.摘要号:P-096
标题:MiR-27b-3p suppresses CD28 expression in T cells and facilitates immune escape of multiple myeloma.
通讯作者:郝牧
单位:中国医学科学院血液病医院
8.摘要号:P-120
标题:Indirubin-3’-monoxime acts as proteasome inhibitor: therapeutic application in multiple myeloma.
通讯作者:郝牧
单位:中国医学科学院血液病医院
9.摘要号:P-165
标题:The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
通讯作者:安刚
单位:中国医学科学院血液病医院
10.摘要号:P-226
标题:Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China.
通讯作者:安刚
单位:中国医学科学院血液病医院
11.摘要号:P-286
标题:Identification of myeloma-initiating cells and novel therapeutic target by single-cell sequencing.
通讯作者:郝牧
单位:中国医学科学院血液病医院
上海交通大学医学院附属仁济医院
1.摘要号:P-059
标题:Chemotherapy-induced transcriptional reprogramming of multiple myeloma revealed by single-cell RNA sequencing.
通讯作者:侯健
单位:上海交通大学医学院附属仁济医院
2.摘要号:P-087
标题:Single-cell RNA sequencing reveals ZNF683 as a key regulator of NK cell exhaustion in multiple myeloma.
通讯作者:侯健
单位:上海交通大学医学院附属仁济医院
3.摘要号:P-285
标题:Single-cell RNA-seq reveals XBP1-SLC38A2 axis as a player in immunosuppressive T lymphocytes in multiple myeloma.
通讯作者:侯健
单位:上海交通大学医学院附属仁济医院
苏州大学附属第一医院
1.摘要号:P-063
标题:The independent adverse prognostic significance of 1q21 gain in newly diagnosed multiple myeloma patients.
通讯作者:吴德沛
单位:苏州大学附属第一医院
上海市静安区闸北中心医院
1.摘要号:P-094
标题:The expression and prognostic significance of piRNA-823 in multiple myeloma.
通讯作者:周帆
单位:上海市静安区闸北中心医院
2.摘要号:P-127
标题:Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma, a real-world analysis.
通讯作者:周帆
单位:上海市静安区闸北中心医院
1.摘要号:P-225
标题:The optimal dose of thalidomide on the treatment of newly diagnosed multiple myeloma: real-world experience in Taiwan.
通讯作者:Chieh-Lin Jerry Teng
单位:台中荣民总医院
2.摘要号:P-274
标题:Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan.
通讯作者: Chieh-Lin Jerry Teng
单位:台中荣民总医院
首都医科大学附属北京朝阳医院
1.摘要号:P-256
标题:Proteasome inhibition prolonged by in-class transitioned ixazomib-based regimen in newly diagnosed and first-line relapsed multiple myeloma patients in China: a real-world study.
通讯作者:陈文明
单位:首都医科大学附属北京朝阳医院
香港大学玛丽医院
1.摘要号:P-266
标题:Favorable outcomes of 3-weekly daratumumab-based regimens in relapsed/refractory multiple myeloma: impact of MRD, rapid doubling time, LDH, triplets and quadruplets.
通讯作者:Chor Sang Chim
单位:香港大学玛丽医院
中国专家参与合作的相关研究入选的Oral专场
1.摘要号:OAB-001
标题:Potentiating T cell activity against multiple myeloma through SUMOylation inhibition
参与作者:Liu Wei
单位:中南大学湘雅医院
2.摘要号:OAB-009
标题:γ-secretase inhibitors augment efficacy of BCMA-targeting T cell engagers against multiple myeloma cells without impairing T cell effector function
参与作者:Lijie Xing,Shih-Feng Cho,
单位:山东第一医科大学,台湾高雄医学大学(中国台湾)
3.摘要号:OAB-031
标题:PHF19 promotes multiple myeloma cell resistant to daratumumab/isatuximab via upregulation in immunosuppressive microenvironment and reduced CD38 target expression
参与作者:邱录贵,郝牧
单位:中国医学科学院血液病医院
2022 IMS 中国名单最新出炉排名不分先后,按摘要号进行,如有遗漏,欢迎大家留言补充!
排版编辑:luna